A Multicenter Phase II Open Label Study to Evaluate Efficacy of Concomitant Use of Pembrolizumab and Entinostat in Adult Patients With Metastatic Uveal Melanoma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Entinostat (Primary) ; Pembrolizumab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- Acronyms PEMDAC
- 30 May 2017 Planned End Date changed from 1 Sep 2021 to 1 Mar 2022.
- 30 May 2017 Planned primary completion date changed from 1 Sep 2019 to 1 Mar 2020.
- 30 May 2017 Planned initiation date changed from 1 Mar 2017 to 1 Sep 2017.